Opioid Abuse Deterrence, Research, and Recovery Act of 2017

Summary

Opioid Abuse Deterrence, Research, and Recovery Act of 2017 This bill amends the Controlled Substances Act to prohibit the Drug Enforcement Administration from registering, or renewing the registration of, a practitioner who is licensed to prescribe opioids in schedule II or III unless the practitioner agrees to limit an opioid prescription for the initial treatment of acute pain to the lesser of a seven-day supply (no refill) or an opioid prescription limit established under state law. Certain opioid prescriptions are not subject to the limit (e.g., an opioid that is approved and prescribed for the treatment of an opioid use disorder). The Food and Drug Administration (FDA) must continue to work with stakeholders to promote the development of abuse-deterrent opioid formulations. The bill requires: (1) the Government Accountability Office to study and report on health care policy changes that may have contributed to the increase in opioid overdoses and deaths, and (2) the FDA to study the feasibility of replacing opioid prescribing limits established by this bill with evidence-based clinical guidelines for opioid prescribing.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 29 November 2017

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 29 November 2017

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 29 November 2017

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.